Pacylex

Pacylex Pharmaceuticals Announces Publication in Nature Communications of a New Target for Therapeutic Intervention in Hematologic Malignancies and Preclinical Results of a First-in-Class Therapy

We are excited to announce the publication in the journal Nature Communications of data showing an N-myristoyltransferase (NMT) inhibitor is effective against several blood cancers including lymphoma and leukemia cell lines and completely regresses tumors in several lymphoma xenograft models. This report also includes mechanistic data demonstrating that inhibition of myristoylation of proteins for the B-cell receptor signalling complex, that are essential for lymphoma cell survival, leads to cancer cell death, supporting this as a new target for cancer therapy.

Below are links for viewing or downloading the material as well as today's press release.

Nature Communications Paper: https://www.nature.com/articles/s41467-020-18998-1

Supplementary material: https://static-content.springer.com/esm/art%3A10.1038%2Fs41467-020-18998-1/MediaObjects/41467_2020_18998_MOESM1_ESM.pdf

DOI: https://doi.org/10.1038/s41467-020-18998-1

Nature Communications press release: https://pacylex.reportablenews.com/pr/pacylex-pharmaceuticals-announces-publication-in-nature


October 22, 2020